Last reviewed · How we verify
sulfadoxine-pyrimethamine / mefloquine
Sulfadoxine-pyrimethamine is a combination of a sulfonamide antibiotic and a dihydrofolate reductase inhibitor, while mefloquine is a blood schizonticide.
Sulfadoxine-pyrimethamine is a combination of a sulfonamide antibiotic and a dihydrofolate reductase inhibitor, while mefloquine is a blood schizonticide. Used for Malaria treatment and prevention.
At a glance
| Generic name | sulfadoxine-pyrimethamine / mefloquine |
|---|---|
| Sponsor | Institut de Recherche pour le Developpement |
| Drug class | Antimalarial |
| Target | Plasmodium falciparum |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Sulfadoxine-pyrimethamine works by inhibiting the growth of the malaria parasite, while mefloquine targets the parasite's schizont stage. This combination therapy is effective against Plasmodium falciparum and other malaria-causing parasites.
Approved indications
- Malaria treatment and prevention
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Dizziness
Key clinical trials
- Dose Escalation PfSPZ-CVac (PHASE1)
- A Comparative Study of Mefloquine and S-P as Prophylaxis Against Malaria in Pregnant HIV + Patients (PHASE1)
- Kilimanjaro IPTi Drug Options Trial (PHASE2, PHASE3)
- Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease (PHASE1, PHASE2)
- Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy (NA)
- Activity of Mefloquine Against Urinary Schistosomiasis (PHASE2)
- Intermittent Preventive Treatment During Pregnancy in Benin (PHASE3)
- Antimalarial Drug Resistance in Mali (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: